Generic lenacapavir has cleared its first major regulatory hurdle: on 2 November 2026 the US Food and Drug Administration granted tentative approval to Hyderabad-based Dr. Reddy’s Laboratories for a generic version of the twice-yearly HIV prevention injection, which partners say will sell for US$40 per person per year across 120 low- and middle-income countries. The decision came 16 months after the FDA approved Gilead’s originator product in June 2025, and first supplies are expected to ship before the end of 2026.
Key takeaways on generic lenacapavir
- Dr. Reddy’s is the first company to win FDA tentative approval for a generic long-acting injectable for HIV prevention.
- Tentative approval confirms the product meets FDA standards but does not allow US sales while Gilead’s patents are in force; it does enable US government-funded procurement abroad.
- The agreed price is US$40 per person per year in the 120 countries covered by Gilead’s voluntary licence.
- Unitaid, Wits RHI and the Clinton Health Access Initiative (CHAI) backed the filing financially, technically and on regulatory strategy.
- First generic doses are expected in countries by end-2026, with wider availability in 2027.
What the FDA actually approved, and what it did not
A tentative approval is the FDA’s standard outcome for a generic that is scientifically ready but blocked by the originator’s patents or exclusivities. It is not a licence to market in the United States. For global health purposes, however, it carries real weight: products with FDA tentative approval can be bought with US government funds for programmes in other countries, and the review gives national regulators a stringent benchmark to lean on.
According to CHAI’s announcement, Dr. Reddy’s combined the prevention and treatment indications into a single application under the 505(b)(2) pathway, a route that earned priority review, which targets an FDA decision within six months. That filing strategy is a large part of why the generic arrived only 16 months after the brand.
The numbers behind the approval
| Metric | Figure |
|---|---|
| Originator (Gilead) FDA approval | June 2025 |
| Dr. Reddy’s FDA tentative approval | 2 November 2026 |
| Gap between brand and first generic | 16 months |
| Dosing frequency | Twice a year (injection) |
| Agreed price in licensed countries | US$40 per person per year |
| Countries covered by Gilead’s voluntary licence | 120 |
| Generic makers licensed by Gilead (late 2024) | 6 |
| People already started on Gilead’s lenacapavir in 10 early-adopter African countries | More than 125,000 |
By our calculation, US$40 a year works out to roughly US$20 per injection, or about 11 US cents per day of protection. The partners describe the price as in line with daily oral PrEP, which matters because programme budgets in high-burden countries have been built around pill costs.
Why a twice-yearly shot changes HIV prevention
Lenacapavir is a capsid inhibitor: it interferes with the protein shell that HIV needs to move its genetic material into a cell’s nucleus and to assemble new virus particles. Because the drug is released slowly from the injection site, one dose covers about six months.
The case for it rests on Gilead’s PURPOSE programme. In PURPOSE 1, which enrolled young women in South Africa and Uganda, no HIV infections occurred among more than 2,100 women assigned to twice-yearly lenacapavir. In PURPOSE 2, which enrolled cisgender men and gender-diverse people across several continents, two infections were seen among more than 2,100 participants on the drug. Both trials were published in the New England Journal of Medicine. The core weakness of oral PrEP has always been adherence; two clinic visits a year sidestep the daily-pill problem. CHAI chief executive Dr. Neil Buddy Shah put it bluntly: two injections a year of a product “almost 100% effective at preventing HIV, changes that entirely.”
The India angle
The approval is another marker of Indian manufacturers’ role as the volume suppliers of the global HIV response, a position built on generic antiretrovirals since the early 2000s. Dr. Reddy’s October 2026 investor presentation referred to an expanded collaboration with Gilead on lenacapavir covering 120 countries, including India. We found no public announcement of a CDSCO approval for lenacapavir in India at the time of writing, so Indian patients should not expect immediate access; that will depend on a separate national regulatory decision and on whether the national programme adopts injectable PrEP.
For the company, the product adds a high-profile global health asset alongside recent regulatory wins such as its Zytorvi approval in esophageal cancer. The commercial upside at US$40 a year is modest per patient; the opportunity is volume, driven by donor-funded procurement.
Limits and open questions
- No US switch yet. People in the United States using Gilead’s brand cannot move to the generic while the tentative status stands.
- Supply ramp. “Before the end of 2026” covers first shipments only; broader volumes are guided for 2027.
- Programme readiness. Injectable PrEP needs HIV testing before each dose and follow-up systems; prevention injections are not a substitute for treatment in people who already have HIV.
- Other licensees. Five more generic makers hold Gilead licences. Additional approvals would add supply and price competition, but none had been announced in the sources we reviewed.
Market context
Long-acting products are entering a market still dominated by daily pills. Acumen Research and Consulting’s oral HIV treatment market report projected the oral HIV treatment segment to reach around US$2,944.5 million by 2027, growing at about 4.1% a year from 2020. That report was last updated in March 2021, so the figures are dated and best read as indicative of a slow-growing, pill-centred baseline that injectables are now beginning to disrupt.
What to watch next
The next milestones are first shipments to early-adopter countries, approvals for the other five licensees, WHO and national regulatory decisions, and any Indian filing. Follow our FDA approvals coverage for updates.
Frequently asked questions
Is generic lenacapavir approved in the US?
It has tentative approval only. That means the FDA found it meets its standards, but it cannot be sold in the US while the originator’s patents apply. It can be procured for programmes outside the US.
How much will generic lenacapavir cost?
US$40 per person per year in the 120 low- and middle-income countries covered by Gilead’s voluntary licence, under a pricing agreement between Unitaid, Wits RHI, CHAI and Dr. Reddy’s.
When will generic lenacapavir be available?
First supplies are expected to reach countries before the end of 2026, with broader availability in 2027.
Is lenacapavir available in India?
India is listed among the countries in Dr. Reddy’s expanded Gilead collaboration, but we found no public CDSCO approval announcement at the time of writing. Access will depend on Indian regulatory and programme decisions.
Sources: Unitaid and CHAI announcements (2 November 2026), Dr. Reddy’s investor presentation (23 October 2026), PURPOSE 1 and PURPOSE 2 publications in NEJM. Market data: Acumen Research and Consulting. This article is for information only and is not medical or investment advice. Last updated 11 November 2026.
